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Abstract
Prior studies of appetite regulatory networks, primarily in rodents, have established that targeted electrical stimulation of
ventromedial hypothalamus (VMH) can alter food intake patterns and metabolic homeostasis. Consideration of this
method for weight modulation in humans with severe overeating disorders and morbid obesity can be further advanced
by modeling procedures and assessing endpoints that can provide preclinical data on efficacy and safety. In this study we
adapted human deep brain stimulation (DBS) stereotactic methods and instrumentation to demonstrate in a large animal
model the modulation of weight gain with VMH-DBS. Female Go¨ttingen minipigs were used because of their dietary
habits, physiologic characteristics, and brain structures that resemble those of primates. Further, these animals become
obese on extra-feeding regimens. DBS electrodes were first bilaterally implanted into the VMH of the animals (n = 8) which
were then maintained on a restricted food regimen for 1 mo following the surgery. The daily amount of food was then
doubled for the next 2 mo in all animals to produce obesity associated with extra calorie intake, with half of the animals
(n = 4) concurrently receiving continuous low frequency (50 Hz) VMH-DBS. Adverse motoric or behavioral effects were not
observed subsequent to the surgical procedure or during the DBS period. Throughout this 2 mo DBS period, all animals
consumed the doubled amount of daily food. However, the animals that had received VMH-DBS showed a cumulative
weight gain (6.160.4 kg; mean 6 SEM) that was lower than the nonstimulated VMH-DBS animals (9.461.3 kg; p,0.05),
suggestive of a DBS-associated increase in metabolic rate. These results in a porcine obesity model demonstrate the
efficacy and behavioral safety of a low frequency VMH-DBS application as a potential clinical strategy for modulation of
body weight.
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Introduction
According to the U.S. Census Bureau statistics (data for 2006),
34.3% of the adult population in the US is considered obese, as
defined by a Body Mass Index (BMI) over 30 kg/m2 (www.census.
gov). For some individuals, obesity factors result in a condition of
morbid obesity (clinically severe; BMI$40) which affects 5.7% of
the population in the U.S. according to national survey data [1].
This condition has many health risk ramifications at both the
individual and societal levels that include hypertension, hyperlip-
idemia, cardiomyopathy, diabetes, hypoventilation disorders,
cholelithiasis, degenerative arthritis, and psychosocial impair-
ments [2].
Present treatments to control morbid obesity include a wide
variety of drugs and nutritional/dietetic counseling but increas-
ingly only gastrointestinal tract surgical procedures, particularly
the Roux-en-Y gastric bypass, have provided successful therapeu-
tic approaches [3,4]. However, prospective analyses from results of
surgical interventions showing undesired side effects and failure of
long-term control of the disease in morbidly obese patients (BMI
40–50 kg/m2) and super obese patients (BMI.50 kg/m2) provide
a rationale for exploring other effective modality options [5–7]. In
particular, it has been suggested that more translational and
preclinical research studies be conducted on the potential role of
DBS that targets the ventromedial hypothalamus (VMH) and
lateral hypothalamus area (LHA) for the treatment of obesity and
food intake disorders [8–10].
Human DBS Applications for Obesity
The potential for hypothalamic DBS clinical applications
related to control of food intake, fat distribution, and body
weight has not been fully explored. Collectively, data from prior
animal studies that demonstrated modulation of food intake with
electrical stimulation have provided the rationale for a small
number of human DBS studies. However, in 2008 and 2010,
two case reports described mixed results on the use of
hypothalamic DBS to produce weight loss [11,12] thus
highlighting the need for evaluation of DBS delivery approaches
that can achieve desired weight modulation without adverse
effects. Such studies can be conducted in a large animal model in
which human DBS stereotactic methods can be evaluated for
efficacy and safety.
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Porcine Models in Obesity and Neuroscience Research
Miniature pigs (minipigs) have gained increasing importance as
an alternative non-rodent species to the dog or monkey for basic
and applied biomedical research. The pig genome relative to that
of the rodent is more closely related to the human genome [13].
Comparisons between the CNS of the rodent and pig show that
the pig’s gyrencephalic brain resembles the human brain more in
anatomy, growth, and development than do the brains of
commonly used small laboratory animals [14]. Also, the relatively
larger size of the minipig brain allows for identification of cortical
and subcortical structures by imaging techniques (MRI, PET,
ventriculography), and the use of clinical stereotactic methods and
instrumentation [15].
Rodent models of obesity have provided a wealth of information
on basic mechanisms modulating hunger and weight regulation.
However, there are several areas where studies in pigs may offer
advantages as a model for aspects of human obesity. Go¨ttingen
minipigs are similar to humans in digestive physiology, dietary
habits, and fat deposition [16]. In the laboratory setting, they can
be provided a normative ‘restricted diet’ regimen, (i.e. a defined
daily food intake according to animal’s age) to maintain a lean
healthy phenotype that results in animals with more ‘standardized’
body weight and physiology for a particular age range. This
‘restricted’ diet regimen’’ pattern (weight gain vs. age) produces a
‘normative’ growth curve as illustrated in Figure 1, that was
derived from pooled data for .400 animals from birth through 2
years (data obtained from the supplier, Marshall BioResources,
NY).
Minipigs will exhibit hyperphagic behavior when food is
provided, ad libitum, analogous to the overeating-craving food
observed in obese humans. This increase in food intake results in
significant weight gain [17,18] relative to animals on a ‘restricted’
diet. Both male and female Gottingen minipigs become obese, as
defined by relative backfat thickness, when fed ad libitum, but the
females gain significantly more body weight.
Under conditions of food presentation in excess of the
‘restricted’ diet, the Go¨ttingen minipig can be used to model
human pathologies linked to obesity [19–21] and to assess
pharmacologic interventions, as was shown in a study that used
liraglutide, a glucagon-like peptide-1 analog [17] to suppress
excessive food intake.
In our study, we used female animals and administered a
normative ‘restricted diet’ regimen that corresponded to 400–
450 g/day of feed for promoting weight maintenance throughout
the pre-DBS period. Subsequently, the daily food was doubled to
900 g/day (i.e., ‘Near ad libitum’) in all animals for a 2 mo period
to establish a controlled condition facilitating obesity, as similarly
used and validated in prior studies [22]. During this period, DBS
was activated in one-half of the animals, and it was hypothesized
that active VMH-DBS would be associated with a reduced weight
gain relative to that in off-DBS animals (Figure 1 illustrates the
hypothesized effect).
Since low frequency (50–60 Hz) VMH-electrical stimulation
negatively modulated weight and food intake in rodent studies, we
hypothesized that similar effects would be achieved by low
frequency VMH-DBS in a Go¨ttingen minipig model of obesity. In
this study, we have shown that stereotactic targeting methods and
instrumentation that have been well-established in human DBS
applications can be adapted to studies in the Go¨ttingen minipig to
demonstrate efficacy of low frequency VMH-DBS for modulation
of body weight gain.
Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health, and all
procedures were approved by the Office of Animal Research
Oversight/Chancellor’s Animal Research Committee at the
University of California, Los Angeles (ARC# 2010-089-01B).
All efforts were made to minimize animal suffering. Surgeries were
performed under general anesthesia with analgesic and antibiotic
administration.
Figure 1. Predicted effect of hypothalamic DBS on weight gain in female Go¨ttingen minipig. Study Design. We hypothesized that low
frequency DBS would reduce the weight gain (¤) or induce a weight loss (red line), based on prior literature data on weight gain in the Go¨ttingen
minipig. Predicted values are also shown for weight changes (&) on a ‘Restricted’ diet (450 g/day) and for further weight gain (%) on a ‘Near ad
libitum’ diet (900 g/day).
doi:10.1371/journal.pone.0030672.g001
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Animals
Sexually mature female Go¨ttingen minipigs (Marshall BioR-
esources, North Rose, NY) aged 9–11 months and weighing 20–
27 kg were entered into the study.
Housing and Feeding
The animals were singly-housed within enclosures (1.161.8 m)
in a dedicated room maintained at 22uC, relative humidity 40%.
The enclosures allowed for visual contact among animals. For the
complete monitoring of food intake, pre- and post-surgery, the
animals were fed once daily between 0730 and 0800 on a
‘Restricted’ diet regimen of 450 g/day (Prolab Mini-pig diet 5P94;
PMI Nutrition International, Brentwood, MO, USA), to promote
normal weight maintenance without the development of obesity
[18,23]. Water was available ad libitum. At one mo after full
recovery following the surgery, all animals (n = 8) received for
2 mo a daily doubled-food feeding, 900 g/day, previously referred
to as a ‘Near ad libitum’ diet regimen [18]. Concurrently, one half
of the animals (n = 4) received DBS continuously (see Figure 1 for
predicted effect). The animals were weighed on the same day, once
weekly, on a mechanical scale (60.2 kg precision) in the morning
prior to their normal feeding time.
Behavioral Observations
The feeding and behavioral observations were conducted by
veterinary and lab personnel blinded to the experimental
conditions. The animals in this study (n= 8) were assessed
individually at specified times pre-surgery, post-surgery, and
during the DBS stimulation period. The motoric and affective
behaviors of all animals were observed for ,4 wks pre-surgery,
and subsequently for 4 wks post-surgery. Observations then
continued for 2 mo, either on-DBS (n = 4) or off-DBS (n= 4,
controls). During 3 d/wk of behavioral testing, the animals were
allowed to run along a 15 m long corridor. Five-point Likert scales
were used to assess motoric behavior (with 1 indicating normal gait
and posture, and 5 indicating pain upon movement and
immobility) and affective behavior (with 1 indicating species-
typical normal affect, and 5 indicating guarding/aggressive
movements). Affective behavior categories consisted of acceptance
of petting, willingness to accept and eat small food treats, absence
of any guarding response at the site of lead or IPG placement, and
resting in a species-typical lateral recumbent position.
Surgery Procedures
The animals were initially anesthetized with Telazol (4 mg/kg,
i.m.) followed by endotracheal intubation. General anesthesia was
maintained by inhalation anesthesia (isoflurane 0.5–2.0%). during
the MR imaging and surgical procedures. A catheter was placed in
the femoral vein for fluid administration. Body temperature,
oxygen saturation, pCO2, and cardiac rate were monitored
continuously throughout the procedures. Following the surgery,
the animals were injected with analgesic Carprofen (0.5 mg/kg,
i.m.) for 3 d and antibiotic Baytril (2 mg/kg, i.m.) for 5 d,
respectively.
MRI
A stereotactic frame designed for a porcine head [24,25] was
secured with four pins to animal’s dorsal skull surface and malar
bones (at temporal or zygomatic process) prior to the stereotactic
procedures (MRI, DBS electrodes implant). Lidocaine (20 mg/ml)
was injected locally at the sites of incisions and of the stereotactic
frame attachment to the head. This animal stereotactic frame was
designed to fit precisely the human Cosmann-Roberts-Wells
(CRW) Radionics stereotactic apparatus (Burlington, MA). A
Radionics MRIA-LF localizer (9 axial fiducials) was attached to
the frame prior to the MR scan (Siemens Symphony, 1.5 Tesla).
The following MR sequences were obtained: Sagittal se T1-
weighted imaging (TR 428 ms, TE 8.6 ms, field of view 230 mm,
slice thickness 2.0 mm, voxel size 1.060.762.0 mm); Sagittal mpr-
ns T1-weighted imaging (TR 2030 ms, TE 3.01 ms, field of view
300 mm, slice thickness 1.3 mm, voxel size 1.261.261.3 mm);
Coronal tse T2-weighted imaging (TR 2500 ms, TE 32.0 ms, field
of view 160 mm, slice thickness 1.2 mm, voxel size
0.860.861.2 mm); Axial tse T2-weighted imaging (TR 2500 ms,
TE 32.0 ms, field of view 160 mm, slice thickness 1.2 mm, voxel
size 0.860.861.2 mm). A coronal reconstruction from the sagittal
volumetric sequence was generated and served as the basis for
stereotactic planning.
VMH Targeting
The VMH target was planned according to regional landmarks
identified in a published stereotactic brain atlas of the Gottingen
minipig species [26–29] and the MR images obtained with the
attached frame and fiducials, using the iPlan 2.6 software
(BrainLab, Feldkirchen, Germany).
Following the stereotactic target planning and target verification
on the phantom, the CRW apparatus with target coordinates
dialed-in, was attached to the frame affixed to animal’s head for
the subsequent stereotactic lead implants. After a midline skin
incision, the dorsal skull surface was exposed and 1.5 mm
diameter holes were drilled bilaterally for the approach to the
hypothalamic targets [30]. A polyimide guide tube (O.D.
1.04 mm, I.D. 0.89 mm; MinVasive Components, Trenton, GA)
fitted with the stainless steel stylet was inserted into the brain and
then the tube was secured to the skull with acrylic adhesive. The
distal tip of the guide tube was stereotactically positioned 4 mm
above the VMH target. The stylet was removed and the
stimulating 4-polar DBS lead was inserted through the guide tube
so that its distal tip protruded 4–5 mm from the tip of the guide
tube into the targeted area of the hypothalamus. A miniature DBS
lead (O.D. 0.64 mm, total length 15 cm, NuMED Inc., Hopkin-
ton, NY) had at its distal end four 90% Pt-10% Ir contacts,
0.5 mm long and spaced 0.5 mm apart.
The accuracy of electrode placement in relation to the set
stereotactic targets was ascertained by intraoperative x-ray
imaging with cross-hair reticles inserted into the CRW frame.
The center of the crosshairs visualized in the image coincided with
the center-of-arc point, i.e., the calculated and dialed-in
stereotactic target for each VMH. Fluoroscopy allowed for
intraoperative corrections of the electrode placement in the
ventral-dorsal direction (Z-axis) and also for verification of the
spacing between electrodes (2–3 mm) inserted parallel to the
midline (Monoplane Philips DSA with intracranial/carotid
protocol; 6 frames/s; Philips Medical Systems North America
Company, Bothell, WA). This entire lead placement method was
used for targeting both left and right VMH. The leads were then
secured to the skull with titanium screws and mini-plates (Stryker,
Kalamazoo, MI) as was recently suggested in a similar procedure
on Go¨ttingen minipigs [31]. A post-implant MR scan was
obtained to verify lead placement and trajectory, in situ.
The proximal ends of the bilaterally implanted leads were
connected to the extension (Dual 4 Channel Extension #3342;
Advanced Neuromodulation Systems (ANS), Plano, TX; a St. Jude
Medical Company) which was tunneled subcutaneously to the
dorsal part of the neck lateral to the right ear of the animal and
connected to the implantable pulse generator (IPG) (Genesis, 8-
Channel #3608, ANS, Plano, TX) which was subcutaneously
VMH-DBS in an Obesity-Animal Model
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implanted. The extension and IPG were secured in place with
non-absorbable sutures. This IPG placement method allowed for
unrestricted and free movement of the animal as well as for
transdermal access for IPG programming and activation without
the need to anesthetize or restrain the animal.
Deep Brain Stimulation
In our study, we used custom-made DBS leads [30] which have
electrodes with a contact area of 0.01 cm2 that are significantly
smaller than the clinical DBS electrode with a contact area of
0.06 cm2. When such small surface area electrodes are used, there
is a concern that excess electric charge can be generated at the
electrode surface that may potentially damage brain tissue. The
relationship between electric charge and electrode surface area is
expressed as charge density (microcoulombs/cm2/phase), i.e., the
quantity of delivered electric charge divided by the surface area.
In prior electrical stimulation and DBS studies in brain,
histologically-detected tissue damage or its absence was deter-
mined following applications of different combinations of
stimulation parameters, [32]. Those studies showed a tissue
damage dependency on stimulation parameters. From those
studies, a plot of charge density vs charge (where charge is the
product of pulse width and current) was used to derive a ‘safety
zone’, i.e., combinations of stimulation parameters that did not
result in tissue damage. Presently, a charge density of 30
microcoulombs/cm2/phase is used as a recommended conserva-
tive upper limit for clinical DBS studies [32] with the commercial
electrodes of defined geometry, although higher charge densities
above that limit are still used (Medtronic SoletraH Neurostimulator
Manual).
Thus, any combination of pulse width, current, and electrode
area that yields less than 30 microcoulombs/cm2/phase is
considered not to result in tissue damage. In Figure 2, we show
for our 0.001 cm2 electrode area, a curve that represents
combinations of pulse width and current resulting in 30
microcoulombs/cm2/phase. Accordingly, any combinations to
the left of that safety-threshold curve could have been selected.
Since we wanted to maintain a low current amplitude for
delivering DBS to a relatively small area of the hypothalamus,
we initially used a low current (0.5 mA) that was matched with a
long PW (507 ms) to achieve a maximal charge density that still
remained ,30 microcoulombs/cm2/phase.
Following the animal’s full recovery from surgery (1 mo), the
IPG was programmed with DBS parameter settings (amplitude:
0.5 mA; Pulse width: 507 ms; Frequency: 50 Hz) and then
activated in a monopolar mode. Contacts 0 and 4, i.e., the most
ventral contacts in the left and right VMH leads, were
programmed as cathode and the IPG case as anode. Those
settings were used for Wks 1, 2, followed by subsequent ramping
up of the amplitude: Wks 3–4 1.0 mA; Wks 5–8 1.5 mA. DBS was
continuously active throughout the entire 8 wk stimulation period.
Measurement of Weight and Blood Glucose Levels
In preliminary studies, we observed that the minipigs showed
small daily weight fluctuations that were likely due to variable
degrees of water and stool retention, as in humans. By design, we
delivered DBS to effect a moderate and progressive weight change
to achieve a statistically significant ‘long term’ result after a 2 mo
DBS stimulation period. The weight measure after that time could
then be reliably used to establish the efficacy of the DBS.
After the 2 mo DBS stimulation period was completed,
preprandial blood samples were obtained (marginal ear vein
puncture) for measurements of blood glucose levels using a glucose
oxidase/electrochemical kit (AgaMatrix, Salem, NH).
Statistics
Our primary outcome measure was cumulative weight change
in the 2 mo period under the condition of either on- or off-DBS.
Since a directional hypothesis was explicitly stipulated in advance
of the study (as shown in Figure 1, i.e., hypothesized weight loss
with time), we used a one-tail t-test to determine statistical
significance. In further support of the use of a directional
hypothesis, the 50 Hz stimulation that we used had been evaluated
in numerous prior studies in rodents and resulted in either reduced
food intake and/or weight loss [33–38]. Presently, there are no
reports of weight gain with similar experimental DBS designs
using low frequency VMH stimulation, as opposed to high
frequency VMH stimulation that we explored in a nonhuman
primate study [30].
Post-Mortem Histology and Immunohistochemistry
After 2 mo of either on- or off-DBS (controls), all animals were
euthanized with pentobarbital (100 mg/kg, i.v.). The brains were
removed within 20 min; 5 mm coronal blocks were obtained and
were frozen for ,30 s in isopentane maintained at 235uC on dry
ice, and then stored at 280uC. For each brain, the block
containing the hypothalamus was cut into 20 mm sections on a
cryostat (Leica CM 3050) maintained at 220uC (chamber
temperature, 215uC cutting head temperature) and thaw-
mounted onto gelatin-subbed slides.
Selected sections were post-fixed for 10 min in acetone at
220uC or in 4% paraformaldehyde solution in 0.1 M PBS,
pH 7.4, at room temperature for 15 min and then stained with
hematoxylin and eosin, and cresyl violet to identify the terminal
region of the implanted electrodes. Adjacent sections were then
immunostained for GFAP. Briefly, slides with acetone fixed
sections were incubated with 0.3% H2O2 solution in PBS for
10 min at room temperature to block endogenous peroxidase
activity, rinsed and preincubated for 1 h in 3% normal horse
serum (NHS) in PBS. Sections were then incubated with mouse
monoclonal anti-GFAP (Millipore, Temecula, CA), 1:200, in PBS
with 3% NHS for 1 h at room temperature. Following rinses, the
Figure 2. Plot of current vs. pulse width values yielding a
charge density (Qp) of 30 mC/cm2/phase. For this study, DBS
delivery was programmed in constant current mode. To determine
initial DBS parameter settings of current (I) and pulse width (PW) that
could be presumed not to cause tissue damage, a safety threshold
curve was generated from PW and I combinations that yielded a charge
density (Qp) of 30 mC/cm2/phase – a clinical reference value used as a
conservative safety threshold for DBS applications. The equation insert
in the graph was used to calculate corresponding PW values for a range
of I values, with A= 0.01 cm2 for the area of the electrode we used and
Qp= 30 mC/cm2/phase. Thus, any I and PW combinations to the left of
the safety-threshold curve could initially be selected.
doi:10.1371/journal.pone.0030672.g002
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sections were incubated with biotinylated horse anti-mouse IgG
(1:200) (Vector Labs, Burlingame, CA) for 1 h and then with ABC
(Vector Labs), 1:200, for 1 h at room temperature. GFAP
immunoreactivity was visualized with DAB with nickel ammoni-
um sulfate enhancement. Sections were counterstained with
Pyronin Y.
Results
Behavioral Observations
The motoric and affective behavior of all animals remained
unchanged throughout the pre-surgery, and the post-surgery off-
DBS and on-DBS periods. The on-DBS animals showed no
adverse reaction to the initial activation of the DBS parameter
setting at (0.5 mA, 50 Hz, PW 507 ms) or, subsequently,
throughout the DBS stimulation when the amplitude was
increased and maintained at 1.5 mA. These conclusions were
based on the animals’ overt behavior in different circumstances
that included being frequently in a recumbent position during the
day when observed through a viewing window on the door outside
of their cage area, their rolling on their side to accept stroking/
petting of their belly area, and maintaining that position for the
duration of the interaction.
Surgery and MRI Procedures
A schematic drawing provides an estimate of the actual target
area occupied by the custom-designed electrode (Figure 3). The
results of previous imaging and histologic studies of Gottingen
minipig brain allowed for accurate stereotactic targeting of
different brain structures in this species [15,29,31,39–41].
Building on these referent results, we defined the VMH target
for DBS in the central part of ventromedial hypothalamic
nucleus. The ovoid shaped ventromedial hypothalamic area in
the Go¨ttingen minipig extends ,3 mm rostro-caudally between
the anterior hypothalamic area and the premammillary nucleus
[42]. The largest coronal VMH cross section with our targeted
central nucleus has dorsal extent of ,2 mm and medial to lateral
extent of ,1.8 mm. The stimulating electrode (diameter
0.64 mm) was targeted to be positioned parallel to the midline
and ,1 mm lateral to the third ventricle so that the two most
ventral contacts passing through VMH encompassed the whole
ventral-dorsal extent of the nucleus. Based on the preoperative
MRI scans that were used for stereotactic surgical planning, the
targeted central part of VMH had coordinates ,10 mm anterior
to the posterior commissure and ,8 mm inferior to the AC-PC
line at the level of the pituitary stalk between the optic chiasm
and the mammillary body.
The iPlan 2.6 software (BrainLab, Germany) was used to derive
the bilateral VMH targets, with confirmation assessed either with
a post-operative MR scan after the leads were implanted (Figure 3)
or with intraoperative fluoroscopy. The trajectories of the
electrodes were observed to terminate in the ventral hypothalamic
region during the cryostat-cutting of the frozen brain block
containing the hypothalamus but could not be visualized in 20 mm
sections (data not shown).
The surgery and MRI procedures were unremarkable. The
animals well-tolerated the general anesthesia (,8 h) and they
regained consciousness within 2 h after its termination at the end
of the surgery. Normal appetite was observed the following day.
Prior to initiation of VMH-DBS, we continued the pre-surgery
standardized food regimen of 450 g/day for 1 mo post-surgery in
order to observe maintenance of pre-surgery weight, affective and
motor behaviors, and to allow complete recovery from the surgical
procedure-DBS lead implants.
VMH-DBS Programming Procedures
The position of IPG in the dorsal part of the neck allowed for
an easy access for programming and activation transdermally
without the need to anesthetize and restrain the animal. Our
initial selection of parameter settings (50 Hz, 0.5 mA, and 507 ms
pulse width) yielded a charge density below the 30 mC/cm2/
phase threshold-safety curve, used for clinical DBS applications
with commercial electrodes (Figure 3). Those settings were used
for first 2 wks of VMH-DBS concurrently with the start of the
900 g/day daily food ration. Since throughout that period a
reduction in food intake was not observed, the current was
increased to 1 mA for the next 2 wks. After this 1 mo of VMH-
DBS, some of the animals showed lesser weight gains relative to
the off-DBS animals on the same 900 g/day food ration. Since all
animals well-tolerated these initial VMH-DBS parameter set-
tings, the amplitude was further increased to 1.5 mA for 4
additional wks for achieving an effect in all animals. The settings
of 50 Hz, 1.5 mA, and 507 ms pulse width resulted in a calculated
charge density of 76 mC/cm2/phase.
Figure 3. Schematic of DBS lead placement in VMH: Fusion of pre-operative targeting with post-operative MR images. Left: Custom-
made DBS leads (O.D. 0.64 mm), were scaled to size for use in the minipig and implanted bilaterally in the VMH regions. The anatomy schematic
(adapted from [42] show a coronal hemisection depicting the area of the VMH region occupied by one DBS lead and the relative location of the most
distal contact that was used for monopolar stimulation (scale bar = 500 mm). Middle and Right: The pre-operative MR scan was fused to the post-
operative MR scan to verify accurate bilateral placement of the 2 DBS leads into the VMH. Images are shown in coronal and sagittal planes. The pre-
operative scan was used to plan the DBS lead trajectories which are represented by the dotted lines. The post-operative scan shows the DBS leads (in
black) which have distorted volumes due to MR artifact.
doi:10.1371/journal.pone.0030672.g003
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Post-Mortem Histology and Immunohistochemistry
H&E histology and GFAP immunostaining did not show
detectable signs of inflammation or reactive gliosis in the VMH
brain region (data not shown).
Weight Gain Modulation with DBS
Throughout the 2 mo of the on-DBS study period, all animals
consumed their daily food within 40 min of presentation. After
2 mo, the animals that had received VMH-DBS showed a mean
cumulative weight gain of 6.160.4 kg (mean 6 SEM) that was
significantly lower than the 9.461.3 kg, measured for the
nonstimulated VMH-DBS animals; one-tailed t-test, p,.05
(Figure 4).
Blood Glucose Levels
After the 2 mo DBS stimulation period, preprandial measure-
ments of morning blood glucose levels (after overnight fasting) in
on-DBS animals were 3.060.3 mM (mean 6 SEM) which were
not significantly different from the glucose levels of 3.260.5 mM
measured in control animals. These glucose levels are within the
range of mean control values (3–4.1 mM) reported for the
Go¨ttingen minipig in prior studies [17,43,44].
Discussion
The rationale for a clinical application of VMH-DBS to treat
morbid obesity and severe eating disorders is based on an
extensive literature demonstrating the regulation of food intake
and satiety by the hypothalamus [45], and the modulation of those
functions by hypothalamic electrical stimulation [8,9].
Consideration of a low frequency VMH-DBS clinical trial can
be advanced upon demonstration of its efficacy and safety in
preclinical studies in which aspects of the clinical procedures have
been modeled. The primary goals of this research were to adapt
human neurosurgical methods and DBS instrumentation for use in
a large animal obesity model and then evaluate the effects of
VMH-DBS on weight modulation and behavior. Our results
showed that in the Go¨ttingen minipig under conditions of extra
calorie intake, the continuous delivery of low frequency (50 Hz)
DBS in the ventral hypothalamus region was associated with a
lower weight gain compared to that in animals not receiving DBS.
Prior Electrical Stimulation Studies in Rodents
In the early 1960’s [46], it was recognized that electrical
stimulation in the range of 60 Hz of the VMH region of the rat
suppressed feeding in animals that were fasted for as long as 5
days. In later studies, VMH stimulation at 50–60 Hz resulted in
inhibition of feeding, reduced food intake, and/or reduced weight
gain [33,47–49]. Increases in lipolysis were also observed [34]
which were attributed to activation of sympathetic pathways to
adipose tissues insofar as sympathetic denervation impaired or
abolished the electrical stimulation response [35,36]. Increases in
metabolic rate and modulation of energy expenditure were also
characterized for this 50–60 Hz range of electrical stimulation
[33,37]. Those results suggested a double effect of electrical
stimulation on energy balance. First, it favored a lipolytic effect by
the utilization of body fat stored in adipose tissue and that resulted
in an anorexigenic effect as characterized by a reduction in food
ingestion as a de-novo energy source. Collectively, these studies
have been invaluable for defining regional effects of hypothalamic
electrical stimulation, albeit with the caveat that most studies were
short term (days to weeks) and were conducted in non-obese
animals.
DBS Applications in the Hypothalamus
DBS represents the clinical counterpart of electrical stimulation
as used in animal studies. Generally, DBS applications in humans
are classified bimodally by frequency range - either high (100–
185 Hz) or low (,100 Hz). Within each mode, further options for
amplitude (either voltage or current) and pulse width then allow
for a wide range of parameter settings combinations. However, in
the absence of a detailed theoretical framework for understanding
how those variables affect neuronal and glial tissues, the clinician
usually uses combinations that follow prior protocols that
demonstrated positive clinical outcomes, and then they further
modify selected settings empirically to maximize efficacy and
minimize adverse effects for individual patients.
Molecular mechanisms underlying the therapeutic effects of
DBS remain not well-defined. Initially, experimental evidence
supported the theory that high-frequency DBS paradoxically acts
like a lesion, i.e., via a neuronal ‘depolarization block.’ However,
more recent studies have shown that while high frequency DBS
does inhibit somatic activity near the DBS electrode, it can also
increase regional output by directly activating axons of local
projection neurons. Additionally, surrounding neuropil can be
stimulated to different extents as the DBS intensity fades radially
from the electrode placement. These ‘secondary’ effects of the high
frequency DBS intensity may be analogous to those primarily
produced by low-frequency DBS which is hypothesized to activate
neurons (cell bodies, axons or both) by enhancing their firing and
responsivity to other neural inputs [50].
Since the early 2000’s, the posterior hypothalamus has been
targeted with high frequency DBS as treatment of cluster
headaches [51], facial pain syndromes, and behavior disorders
[52,53]. For example, low frequency (15 Hz) posterior hypotha-
lamic DBS with a relatively low amplitude and long pulse width
(0.1–0.4 V, 450 ms) was applied for treatment of drug-resistant
aggressiveness in a mentally retarded patient [54]. In contrast, the
hypothalamus as a novel target for low frequency DBS in humans
has been reported only recently in case reports. Relevant to our
preclinical study, hypothalamic DBS effecting changes in body
weight in humans was described for a single morbidly obese male
Figure 4. Effects of low frequency VMH-DBS on weight gain in
female Go¨ttingen minipigs. After bilateral placement of DBS leads
into the VMH followed by a 1 mo recovery period, monopolar
stimulation was delivered continuously for 2 mo. The DBS parameters
included 50 Hz and 509 ms pulse width with current of 0.5 mA for
2 wks, then 1 mA for 2 wks, and 1.5 mA for 4 wks. For that entire 8 wk
period on-DBS, the maintenance ‘Restricted’ daily food ration of 450 g/
day was doubled to 900 g/day (the ‘Near Ad Libitum’ Diet) for all
animals. Both on-DBS (n = 4) and off-DBS (nonstimulated controls; n = 4)
animals ate their entire daily food rations. The 8 wk cumulative weight
gain for animals on-DBS (6.160.4 kg; mean 6 SEM) was significantly
lower than that for animals off-DBS (9.461.3 kg), p,.05).
doi:10.1371/journal.pone.0030672.g004
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[11]. In this case report, weight loss of ,6% body weight over
5 mo without changes in diet or exercise habits was observed only
with low frequency DBS (50 Hz, 3.0–4.0 V, 210 ms) in the VMH
area. No such effects were observed with high frequency (130 Hz)
over 6 mo. When the low frequency VMH-DBS was turned off,
the subject regained the weight he had previously lost, suggesting
reversibility of the DBS effect. Another case report on the failure of
DBS for weight control in a morbidly obese individual mostly
described an adverse effect associated with the procedure [12].
Neither of these case reports explicitly discussed their applied DBS
parameters or their postulated effects in terms of weight control.
Here, we attempted to address several of those issues. Firstly, we
needed to develop and validate in our lab a large animal model of
morbid obesity in which DBS instrumentation and methods could
be applied. We greatly benefited from a wide range of prior brain
studies in the Go¨ttingen minipig conducted by the Danish group
over the last 10 years. In particular, their delineation of the
hypothalamus cellular topography clearly indicated its potential
applicability for VMH-DBS [42]. Further, studies by Bollen et al.
[18,23,55] characterized many aspects of the female Go¨ttingen
minipig normal physiology and its natural predisposition to
become obese with extra calorie intake, thus establishing it as a
model for aspects of human obesity. With these prior character-
izations of the Go¨ttingen minipig, we readily developed and
validated under our lab conditions both maintenance and extra-
calorie food intake conditions to be used to test the efficacy of
bilateral VMH-DBS for modulating food intake and/or body
weight.
Accurate targeting of DBS electrodes to deep structures of the
brain, e.g., the hypothalamus, is challenging since small initial
trajectory errors are magnified as the depth of insertion increases.
Also, transiting across cerebral ventricle membranes enroute to
hypothalamus can cause distortion in the trajectory. We
significantly obviated those issues with the use of a guide tube to
support the minielectrode [30]. The guide tube was implanted
with a stainless steel stylet (removed after securing the guide tube)
which passed through the trajectory just proximal to the target
without mechanical deformation. The electrode was then passed
through the guide tube to reach the intended target. Intraoperative
fluoroscopy was then used for target confirmation and to make 1–
2 mm adjustments in trajectory depth and final positioning
(ventral) of the electrode in the target region.
Our prior experience with neurosurgical stereotactic methods,
instrumentation and MR imaging for implementing DBS in the
human [56–58] facilitated their adaptation to the minipig brain.
We achieved precise VMH targeting as evidenced by the DBS
post-operative MR imaging and post-mortem histology. No
significant adverse behavioral effects were observed following the
DBS surgery or throughout the DBS stimulation period. The DBS
IPG that was subcutaneously implanted in the dorsolateral
shoulder region allowed for accessible programming in the
conscious and unrestrained animal. Thus, the adaptation of DBS
clinical instrumentation (clinical IPG, and connector) could be
coupled with an electrode scaled to size for the minipig
hypothalamus (electrode diameter: 0.64 mm/animal vs 1.5 mm/
clinical).
However, the selection of the initial DBS parameter settings was
not evidence-based since the effects of systematic variations of low
frequency VMH-DBS stimulation and pulse widths over long
periods of time (wks, mo) in any animal species had not been
previously described. Accordingly, we selected the stimulation
frequency of 50 Hz, based on experimental literature of VMH
electrical stimulation showing that a majority of studies with 50 Hz
(range: 10–100 Hz) resulted in either a reduction of food intake or
an increase in energy utilization. We activated the most distal
electrodes with a monopolar configuration to presumably affect a
larger VMH region. As our main read-outs on VMH-DBS efficacy
were the amount of daily food consumption and weekly weighing,
we needed to maintain the same DBS settings for at least 2 wks to
determine any significant change. Since our initial DBS settings
were without apparent effect for 1–2 wks, we increased the
amplitude to 1 mA and then observed a reduced increase in
weight (,1 kg) from the previous wk in 2 of 4 animals, suggestive
of a DBS effect. Insofar as all animals appeared to well-tolerate the
VMH-DBS, we increased the current to 1.5 mA in all animals
which was then continued for the second mo of stimulation. This
resulted in a charge density of 76 mC/cm2/phase. Although that
value was higher than the 30 mC/cm2/phase limit recommended
for clinical applications with the commercial electrodes, it was
within a ‘no tissue damage-zone’ derived from multiple non-DBS
electrical stimulation and DBS clinical studies [59,60]. In clinical
applications, combinations of low frequency (50–60 Hz) and long
pulse width (400–507 ms) will not likely be a safety issue concern
insofar as the larger surface area of clinically used DBS electrodes
(0.06 cm2) yields a charge density within the recommended safety
zone.
The present study design with the read-out of weight change
did not allow for accurate assessments of alternating short periods
of 1–2 wks with on- and off-DBS. However, it was not our
intention to induce significant weight fluctuations acutely with
DBS since such short term effects may not extrapolate to a safe,
long term human application. The overall effect of the VMH-
DBS treatment for a 2 mo period of continuous stimulation did
result in a significantly lower weight gain of ,10% relative to
weight-matched DBS-off ‘controls’ for the same period of extra-
calorie intake. We tentatively attribute this lower weight gain to
an increase in metabolic rate insofar as all animals ate their entire
daily food ration within 30–40 min of presentation throughout
the 2 mo DBS period. This study was not designed to measure
changes in metabolic rate, but now having established an effective
set of VMH-DBS parameters, future studies employing indirect
calorimetry to measure increases in metabolic rate would provide
confirmatory data. Further, the use of that method would be ideal
for conducting parameter sweeps of DBS settings that can be
readily evaluated for their efficacy and reversibility. A VMH
DBS-induced increase in metabolic rate has some support from
prior experimental and clinical studies. In rodents, electrical
stimulation in the hypothalamus resulted in metabolic rate
increases [33–38]. In humans, a case report showed that a male
subject lost weight during VMH DBS without changing his eating
habits or his physical activity, suggestive of an increase in
metabolic rate.
In conclusion, this study has demonstrated that clinical
neurosurgical instrumentation and methods can be applied to
preclinical studies in a large animal model. We also demonstrated
that DBS leads and electrodes can be scaled down to appropriate
size for use in the minipig brain. The DBS that was targeted to the
ventral hypothalamus of the Gottingen minipig effected a
reduction in weight gain under conditions of extra-calorie intake.
These results show that DBS can provide CNS neuromodulation
within the hypothalamus and provide preclinical evidence in
support for this DBS application as a potential strategy for the
treatment of humans with morbid obesity.
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